FDA Grants New Indication for Abrysvo for At-Risk Adults From 18 to 59

The FDA granted a new indication for Pfizer’s Abrysvo RSV vaccine for younger adults whose chronic condition ...

OCTOBER 24, 2024

Top-Down Therapy Proves Its Worth in Crohn’s Disease

Adults newly diagnosed with active Crohn’s disease benefit from immediate treatment with advanced therapies, ...

APRIL 22, 2024

For De-escalation of IBD Therapy, New Data Support Stopping Immunomodulators

If de-escalating IBD therapy, cutting out the immunomodulator but keeping the anti-TNF agent may be the best bet, ...

JULY 31, 2023

Racial Disparities Seen in Use of IBD Medical Therapy

Black patients with IBD are less likely to be treated with certain therapies than white IBD patients, according to ...

JANUARY 14, 2023

Treatments for Immunotherapy-Induced Colitis Might Affect Cancer Outcomes

Biologic agents commonly used to treat gastrointestinal problems associated with the use of immune checkpoint ...

NOVEMBER 10, 2021

Older With IBD: Safety and Efficacy of Combination Therapy

Kian Keyashian, MD, a clinical assistant professor of medicine in the Division of Gastroenterology and Hepatology ...

DECEMBER 23, 2019

AGA Issues Treatment Recommendations For Moderate to Severe UC

New guidelines from the American Gastroenterological Association call for the use of biologics or the ...

NOVEMBER 6, 2019

Combo Therapy Can Delay Loss of Response To Anti-TNF Agents for IBD

Although roughly four in 10 patients with inflammatory bowel disease who receive anti–tumor necrosis factor ...

AUGUST 26, 2019